TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01391962

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lomotil
Description: 2.5mg plus atropine sulfate 0.025mg/tablet dosed according to package insert.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lomotil
Description: 2.5mg plus atropine sulfate 0.025mg/tablet dosed according to package insert.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Loperamide
Description: 4mg by mouth (PO) after first unformed stool with 2mg PO every 2 hours as long as unformed stools continue.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Loperamide
Description: 4mg by mouth (PO) after first unformed stool with 2mg PO every 2 hours as long as unformed stools continue.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vitamin B6
Description: 50-150mg orally each day for hand-foot syndrome.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vitamin B6
Description: 50-150mg orally each day for hand-foot syndrome.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aquaphor
Description: Topical emollient for hand-foot syndrome.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aquaphor
Description: Topical emollient for hand-foot syndrome.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Analgesic for hand foot syndrome as needed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Analgesic for hand foot syndrome as needed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levothyroxine
Description: Replacement therapy for participants with increases in thyroid-stimulating hormone.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levothyroxine
Description: Replacement therapy for participants with increases in thyroid-stimulating hormone.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: 2mg daily for prophylaxis of thrombosis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: 2mg daily for prophylaxis of thrombosis.
Study: NCT04291781

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RC18 160mg
Description: subcutaneous injection on the upper arm, abdomen, or upper thigh outside;

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RC18 240mg
Description: subcutaneous injection on the upper arm, abdomen, or upper thigh outside;

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: subcutaneous injection on the upper arm, abdomen, or upper thigh outside;
Study: NCT04011176

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Standard treatment + placebo
Description: Placebo microcurrent

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard treatment + Microcurrent Therapy
Description: Actual microcurrent
Study: NCT03536572

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Apnea Self-Management Program
Description: Protocol-based sleep apnea and CPAP education and support

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Apnea Self-Management Program
Description: Protocol-based sleep apnea and CPAP education and support
Study: NCT03131024

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 50% caloric restriction
Description: Meals mimicking participant dietary preferences and matching North American macronutrient guidelines will be provided consisting of 50% of total caloric intake for 48 hours

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: The supervised exercise session will consist of a 10-minute warm-up, 30 minutes performed at 70-75% of heart rate reserve, which corresponds to a vigorous intensity, followed by a 5-minute cool-down
Study: NCT03879512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: depletion of regulatory T cells
Description: oral metronomic cyclophosphamide

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: reoperation
Description: resection of relapsed tumor in order to improve clinical condition of the patient and to acquire tumor tissue for vaccine generation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cancer vaccine
Description: 4 weekly intradermal injections of lysate-loaded dendritic cells, followed by 3 monthly boost vaccines with tumor lysate and further boost vaccines every three months

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: checkpoint blockade
Description: Immediately one week after the DC-induction vaccines, patients will receive four applications of Nivolumab/Ipilimumab double checkpoint blockade in threeweekly intervals, followed by Nivolumab monotherapy every month for a total duration of one year.
Study: NCT03815929

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol 100 Micrograms Patch
Description: Standard

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol Patch
Description: Individualized
Study: NCT04544813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-77474462
Description: Participants will receive JNJ-77474462 as a liquid formulation in Cohort A, B, C, D, F and G (SC injection) and in Cohort E, H and I (IV infusion).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-77474462
Description: Participants will receive JNJ-77474462 as a liquid formulation in Cohort A, B, C, D, F and G (SC injection) and in Cohort E, H and I (IV infusion).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-77474462
Description: Participants will receive JNJ-77474462 as a liquid formulation in Cohort A, B, C, D, F and G (SC injection) and in Cohort E, H and I (IV infusion).
Study: NCT04544813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-77474462
Description: Participants will receive JNJ-77474462 as a liquid formulation in Cohort A, B, C, D, F and G (SC injection) and in Cohort E, H and I (IV infusion).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-77474462
Description: Participants will receive JNJ-77474462 as a liquid formulation in Cohort A, B, C, D, F and G (SC injection) and in Cohort E, H and I (IV infusion).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-77474462
Description: Participants will receive JNJ-77474462 as a liquid formulation in Cohort A, B, C, D, F and G (SC injection) and in Cohort E, H and I (IV infusion).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-77474462
Description: Participants will receive JNJ-77474462 as a liquid formulation in Cohort A, B, C, D, F and G (SC injection) and in Cohort E, H and I (IV infusion).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-77474462
Description: Participants will receive JNJ-77474462 as a liquid formulation in Cohort A, B, C, D, F and G (SC injection) and in Cohort E, H and I (IV infusion).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-77474462
Description: Participants will receive JNJ-77474462 as a liquid formulation in Cohort A, B, C, D, F and G (SC injection) and in Cohort E, H and I (IV infusion).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anakinra
Description: Participants will receive a SC injection of anakinra 100 mg once daily for 3 days.
Study: NCT03571438

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: CK2 and ATM inhibitors serine/ threonin Kinase combination
Description: Treatment of cell culture with CK2 and ATM inhibitors serine/ threonin Kinase combination

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sunitinib
Description: Treatment of cell culture with Sunitinib

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pazopanib
Description: Treatment of cell culture with Pazopanib

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temsirolimus
Description: Treatment of cell culture with Temsirolimus
Study: NCT02620774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftolozane/tazobactam
Description: 3 or more doses of ceftolozane/tazobactam intravenously administered over 60 minutes every 8 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ceftolozane/tazobactam
Description: 3 or more doses of ceftolozane/tazobactam intravenously administered over 60 minutes every 8 hours

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microdialysis Catheter Insertion
Description: A 20 kila-Dalton microdialysis probe (63 MD catheter; MDialysis Inc., N. Chelmsford, MA) will be inserted into the subcutaneous tissue at the margin of the wound (patient group) or in the thigh tissue (healthy volunteers). The probe will be left in place for the final dose and all tissue sampling procedures thereafter. This probe is perfused with a physiologic solution to collect interstitial fluid samples. The probe will then be removed after completion of sample collection.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microdialysis Catheter Insertion
Description: A 20 kila-Dalton microdialysis probe (63 MD catheter; MDialysis Inc., N. Chelmsford, MA) will be inserted into the subcutaneous tissue at the margin of the wound (patient group) or in the thigh tissue (healthy volunteers). The probe will be left in place for the final dose and all tissue sampling procedures thereafter. This probe is perfused with a physiologic solution to collect interstitial fluid samples. The probe will then be removed after completion of sample collection.
Study: NCT06054126

Intervention type: OTHER
Intervention: Echocardiography
Description: Cardiac function was evaluated by echocardiography at one year follow-up.

Intervention type: OTHER
Intervention: Echocardiography
Description: Cardiac function was evaluated by echocardiography at one year follow-up.
Study: NCT01564160

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fish Oil
Description: Source of omega-3 fatty acids.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PCSO-524
Description: Extract of Greenshell Mussel
Study: NCT01623570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pergoveris: 150IU r-hFSH + 75IU r-hLH
Description: Fixed formulation of two recombinant gonadotropins

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Menopur: HMG-HP (150 IU)
Description: Human Menopausal Gonadotropin is an urinary estract from menopausal women containing 150IU of FSH and 150 IU of LH-like activity (HCG)
Study: NCT04516447

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZN-c3
Description: Investigational drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZN-c3
Description: Investigational drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZN-c3
Description: Investigational drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZN-c3
Description: Investigational drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZN-c3
Description: Investigational drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin is an approved drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin
Description: Pegylated liposomal doxorubicin (PLD) is an approved drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel is an approved drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine is an approved drug

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Combined with azenosertib
Study: NCT03774654

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: CD19.CAR-aNKT cells
Description: Patients will be given the T-cell product by intravenous injection (into the vein through an IV line) at the assigned dose..~Dose Level 1: 1 x 10\^7/m2. Dose Level 2: 3 x 10\^7/m2. Dose Level 3: 1 x 10\^8/m2. Dose Level 4: 3 x 10\^8/m2.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: CD19.CAR-aNKT cells
Description: Patients will be given the T-cell product by intravenous injection (into the vein through an IV line) at the assigned dose..~Dose Level 1: 1 x 10\^7/m2. Dose Level 2: 3 x 10\^7/m2. Dose Level 3: 1 x 10\^8/m2. Dose Level 4: 3 x 10\^8/m2.
Study: NCT02898181

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromodulation
Description: Active LLTS will be performed by use of a transcutaneous electrical nerve stimulation Parasym neuromodulation system with electrodes attached to the ear. Neuromodulation will be applied continuously for 2 hours daily.
Study: NCT03056794

Intervention type: OTHER
Intervention: No intervention
Description: This is an observational study. The investigators will collect data about exposure to responses to dietary supplements, medications, and the ketogenic diet.
Study: NCT04606134

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Hybrid fractional laser
Description: two treatments given one month apart

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hybrid fractional laser
Description: two treatments given one month apart
Study: NCT01819259

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study: NCT03805620

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined physical-cognitive training
Description: combined physical-cognitive training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical training
Description: Multi-component physical exercise

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive training
Description: cognitive training
Study: NCT01283477

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACUPUNCTURE AT LI11
Description: ACUPUNCTURE AT LI11 FOR 30 MINUTES PRIOR TO INTRATHECAL MORPHINE \& LEFT IN PLACE FOR 30 MINUTES

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SHAM ACUPUNCTURE
Description: SHAM ACUPUNCTURE AT A POINT 2 CM LATERAL TO LI11 30 MINUTES PRIOR TO INTRATHECAL MORPHINE \& LEFT IN PLACE FOR 30 MINUTES
Study: NCT04606134

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alastin Regenerating Skin Nectar with TriHex Technology
Description: applied twice daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cetaphil face cream
Description: applied twice daily
Study: NCT00467688

Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: Real time access to current glucose values during CGMS
Description: One arm gets real time access to current measured glucose values and hypoglycemic or hyperglycemic alerts are elicited, The second arm get´s a retrospective analysis of glucose values

Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: Real time access to current glucose values during CGMS
Description: One arm gets real time access to current measured glucose values and hypoglycemic or hyperglycemic alerts are elicited, The second arm get´s a retrospective analysis of glucose values
Study: NCT02717234

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral Nutrition Supplement
Description: Oral nutrition supplement intended for consumption at 3 servings per day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral Nutrition Supplement
Description: Oral nutrition supplement intended for consumption at 3 servings per day
Study: NCT03564808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSC
Description: Adipose tissue enriched with mesenchymal stem cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSC
Description: Adipose tissue enriched with mesenchymal stem cells
Study: NCT03871777

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Placebo mouthwash
Description: Participants received placebo mouthwash (ultrapure unflavoured water) with which they rinsed their mouth for one minute, twice a day for 7 days. Resting metabolic rate and blood pressure were measured on day eight. Additionally, blood and saliva samples were taken from all the participants. Dietary records of seven days were also collected in order to confirm the foods and portion sizes consumed, preparation methods, recipes and any brand names.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo mouthwash
Description: Participants received placebo mouthwash (ultrapure unflavoured water) with which they rinsed their mouth for one minute, twice a day for 7 days. Resting metabolic rate and blood pressure were measured on day eight. Additionally, blood and saliva samples were taken from all the participants. Dietary records of seven days were also collected in order to confirm the foods and portion sizes consumed, preparation methods, recipes and any brand names.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Chlorhexidine mouthwash
Description: After using placebo and complete all the physiological measurements, participants were given a further one-week supply of antibacterial mouthwash containing 0.2% chlorhexidine (Corsodyl, GlaxoSmithKline, UK), encouraged to rinse their mouth for one minute, twice a day for 7 more days. They returned to the laboratory in 7 days to repeat all measurements in the same order.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine mouthwash
Description: After using placebo and complete all the physiological measurements, participants were given a further one-week supply of antibacterial mouthwash containing 0.2% chlorhexidine (Corsodyl, GlaxoSmithKline, UK), encouraged to rinse their mouth for one minute, twice a day for 7 more days. They returned to the laboratory in 7 days to repeat all measurements in the same order.
Study: NCT04634422

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Plasma exchange and convalescent plasma
Description: In addition to standard care, participants will receive 2 plasma exchange procedures max. 30 hours apart using the membrane or centrifuge method. PLEX will be initiated within 30 hours of randomization. The exchange volume of 60 mg of plasma per kg body weight will be substituted with albumin 5% and Ringer/saline 50% at the beginning followed by 50% FFP towards the end of the procedure. At the end of the 2nd procedure, participants will receive additional 2 units of CCP (equalling 600 ml CCP) with an administration rate of 100 to 250 ml/hr. Anticoagulation may be provided by citrate or by heparin but it is suggested that in patients with active bleeding regional citrate anticoagulation be utilized. PLEX may be performed via a central venous catheter if patient is deemed unsuitable for peripheral venous access, the latter is recommended. Possible SAE related to PLEX+CCP will be recorded as air embolism, anaphylaxis, TRALI and reported as an outcome.
Study: NCT03413891

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: Mouthwash

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Mouthwash
Study: NCT03842358

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hand-held hybrid probe
Description: Consists of a commercially available US transducer located in the middle and near-infrared source and detector optical fibers distributed at the periphery

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hand-held hybrid probe
Description: Consists of a commercially available US transducer located in the middle and near-infrared source and detector optical fibers distributed at the periphery
Study: NCT04123470

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: delolimogene mupadenorepvec
Description: LOAd703 is an oncolytic adenovirus encoding TMZ-CD40L and 4-1BBL

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: atezolizumab
Description: Atezolizumab is an anti-PD-L1 antibody
Study: NCT03649880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ¹⁸F-Fluoromisonidazole
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo PET/MRI or PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oxygen Therapy
Description: Receive supplemental oxygen
Study: NCT04137952

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: size of error visual feedback
Description: The strategies are expected to enhance opportunities of error experience and motor exploration via modified visual feedback, underlying facilitations of attentional resource and error-related neural networks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: size of error visual feedback
Description: The strategies are expected to enhance opportunities of error experience and motor exploration via modified visual feedback, underlying facilitations of attentional resource and error-related neural networks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: size of error visual feedback
Description: The strategies are expected to enhance opportunities of error experience and motor exploration via modified visual feedback, underlying facilitations of attentional resource and error-related neural networks.
Study: NCT04139733

Intervention type: PROCEDURE
Intervention: Prone positon
Description: Prone position within 24 hours after VV-ECMO support. Prone position for at least conservative hours per day for a minimum of 5 days.

Intervention type: PROCEDURE
Intervention: Supine positon
Description: Conventional supine position ventilation, no prone position.
Study: NCT03712813

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Macrodyne LivMD plate
Description: Synchronous (applied to both feet) low intensity vibration for 10 minutes, twice daily for 12 months.
Study: NCT03818256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miricorilant
Description: Miricorilant 600 mg (6 X 100 mg tablets) for once-daily oral dosing

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets for once-daily oral dosing
Study: NCT03587961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Symdeko
Description: explore the use of off-label CFTR modulators that may affect CFTR function in patients with CFTR mutations that are not currently approved for these drugs.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Symdeko
Description: explore the use of off-label CFTR modulators that may affect CFTR function in patients with CFTR mutations that are not currently approved for these drugs.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Symdeko
Description: explore the use of off-label CFTR modulators that may affect CFTR function in patients with CFTR mutations that are not currently approved for these drugs.
Study: NCT04540393

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AZD1222
Description: Participants will receive 2 doses of AZD1222; the first dose will be administered on Day 1 and the second dose on Day 29. Unit dose strength(s) \> 0.7 × 1011 vp/mL. Dosage level(s) 5 ×1010 vp (nominal). Route of administration Intramuscular injection